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                                          INTRODUCTION
               Coronary Artery Disease(CAD)  has been defined as impairment of heart function due 
to inadequate blood flow to heart (WHO 1982) 1.
               CAD has become an important epidemiological significant disease in developed as 
well as developing countries. There has been a large increase in incidence of cardiovascular 
disease in recent past in Indian subcontinent. A recent study by ICMR shows the prevalence 
rate has been found to be 80-120/1000. By the year 2015, It  is predicted that CAD would 
replace the infectious disease as the major cause for mortality.  An increase in mortality by 
103% in males &about 90% in females from 1985-2015 is expected 2.
               Acute Myocardial Infarction results from prolonged Myocardial ischemia precipitated  
in most cases by occlusive thrombus at the site of preexisting Atherosclerotic plaque.
               A steady decline in the mortality rate from ST Elevation Myocardial infarction 
(STEMI) has  been observed across  several  population group since19603.  Several  phases in 
management of patients have contributed to decline in mortality from STEMI 4. The “clinical 
observation phase”  in first half of twenth century focused on physical and laboratory finding 
where as treatment is bed rest and sedation. Subsequently “coronary care unit phase” in mid 
1960 was noted for detailed analysis and vigorous management of cardiac arrhythmia . “The 
high technology phase” setting the stage of bed side haemodynamic monitoring. The “Modern 
reperfusion  era”  of  coronary  care  was  introduced  by  intracoronary  and  then  intravenous 
fibrinolysis  and development of  PCI which revolutioned the management and declined the 
mortality of STEMI.
               Large clinical trials have definitively shown the value of thrombolysis in acute  
myocardial  infarction  5-7.  Thus  attention  shifted  to  increase  the  use  of  this  therapy. 
Furthermore ,there and other trails have shown that benefit of this therapy can be maximized 
with earlier treatment 8,9, that is benefit of thrombolytic therapy are greater in first hour after 
onset of symptoms. Important delay in administration of this treatment  have been observed 10-
13. These delay may reduce the efficacy of thrombolysis by increasing not only mortality 14 but 
also morbidity 15. The Goal for the patient with STEMI should be to achieve a door to needle 
time with in 30 min and a door to balloon time within 90 min 16
               The present study is to analyze the delay in thrombolytic therapy in myocardial 
infarction.
          
                                                                        AIM
1. To determine the Prehospital and Door to needle time in thrombolytic therapy in ST-
elevation Myocardial Infarction(STEMI).
2. To evaluate  the influence of  patient’s  clinical  characteristic  in delay in  thrombolytic 
therapy in ST-elevation Myocardial Infarction.
                                        REVIEW OF LITERATURE
                            ACUTE CORONARY SYNDROMES
               Acute coronary syndromes (ACS) is a term used to encompass the spectrum of 
clinical disorders caused by acute ischemic heart diseases, including unstable angina, non -ST 
-elevation myocardial infarction, and ST- elevation myocardial infarction.
Initial classification:
            Therapeutic decisions are required before patients with Acute coronary syndromes can 
be categorized into unstable angina or acute MI based on serum cardiac markers and serial 
ECGs. To facilitate early management, patients are classified into
1. ST-elevation ACS :
                               Also been labeled as “reperfusion eligible” ACS , since prognosis is 
improved by early reperfusion with percutaneous coronary intervention (PCI) or thrombolytic 
therapy. 
                           This  consist of ST  elevation>1mm in 2 or more contagious leads in ECG.  
Patients with left bundle branch block (LBBB) or isolated posterior MI also included in these 
as they also benefit from reperfusion therapy.
2. Non- ST-elevation ACS:
                    This consist of  unstable angina and Non- ST- elevation MI
                           They  are not benefited by Thrombolytic  therapy.
      
              Overall view  of  Acute Coronary Syndromes                    
Features ST-elevation ACS Non-ST-elevation ACS
 Initial therapy
Primary PCI with stents.
Thrombolytic  therapy  if  a 
cath  lab  with  a  skilled 
interventionalist and team is 
not  available  in  a  timely 
fashion.
PCI with stents plus antithrombin 
therapy  and  a  GP  IIb/IIIa 
inhibitor for high risk and some 
intermediate risk patient.
Antithrombin  therapy  for  all 
other  hospitalized  patient 
followed  by  cath/PCI  for 
recurrent  ischemia  or  high  risk 
finding on noninvasive testing.
 Prognosis
Acute  mortality  25-30%. 
Inhospital  survival  depends 
on  speed  and  adequacy  of 
reperfusion.
In-hospital  MI  or  death  in 
unstable  angina  varies  from  1-
5%, depending on risk class.
Non-ST-elevation  MI  has  lower 
hospital  mortality  than  ST-
elevation  MI but  similar  1  year 
mortality due to more late events.
    
             
                                 ATHEROTHROMBOSIS
Atherosclerosis
                      Atherosclerosis is a chronic immunoinflammatory, fibroproliferative disease  
fueled  by  lipids17.  Coronary  atherosclerosis  is  the  underlying  cause  of  nearly  all  cases  of 
ischemic heart  disease  ,  and superimposed thrombosis  is  the  proximate  cause  of  the  great 
majority  of  the  life  threatening  acute  coronary  syndrome(unstable  angina,  myocardial 
infarction, and sudden death)18,19  Atherosclerosis affects primarily the intima of medium sized 
and large arteries, resulting in intimal thickening ,and leads to narrowing and inadequate blood 
supply.
               The  earliest  lesion  of  atherosclerosis  is  the  fatty  streak,  which  is  a  pure 
immunoinflammatory reaction within intima, consisting of lipid filled macrophage (foam cell ) 
and T lymphocytes. There is no extracellular lipid and so as B cells and neutrophils.
               In  advanced atherosclerotic  lesion  (plaques),  lipids  begin  to  accumulation 
extracellularly There is also accumulation of connective tissue produced by smooth muscle 
cells  which  gives  rise  to  very  heterogeneous  atherosclerotic  plaque.  Because  of  leaky 
endothelium ,not only lipoproteins but also many other blood derived components  including 
albumin and fibrinogen, are present in evolving lesion.
                 The flow limiting potential of an intimal plaques maybe modified by reactive  
changes in the underlying media and adventitia that may attenuate (positive remodeling) or 
accentuate ( negative remodeling) luminal obstruction and consequent haemodynamic impact 
of the plaque.
Rupture prone plaques
                The risk of plaque rupture depend more on plaque composition than on the degree of  
stenosis produced by the plaque. Many rupture prone plaques are invisible angiogrphically (and 
also missed by stress testing) due to their small size and compensatory   vascular remodeling 
.Studies have identified three major determinant of plaque’s vulnerability to rupture20:
1. The size of lipid core,
2. Inflammation with plaque degradation and
3. Lack of smooth muscle cells with impaired healing.
              Sudden rupture of plaque may occur spontaneously, But  triggers like severe exertion  
also play a role and thus explain the nonrandom onset of acute coronary syndrome.
Thrombosis
               Rupture of plaque leads to thrombosis. In coronary thrombosis,the initial flow 
obstruction  is  usually  caused by platlet  aggregation,  but  fibrin  is  important  for  subsequent 
stabilization of the early and fragile platelet thrombus 21 
There are three major determinants of the thrombotic response to plaque rupture or the amount 
of thrombosis formed on top of an eroded plaque22:
1. Local thrombogenic substrate
2. Local flow disturbance, and 
3. The systemic thrombotic property.
               The exposure of the highly thrombogenic lipid rich core to circulating blood, resulting 
in activation of primary and  secondary hemostasis.
Primary hemostasis(platelet plug formation):
        Plaque rupture induces platelets to proceed through adhesion, activation, and aggregation. 
  Platelet adhesion:
               It  is initiated by the binding of Von Willibrand factor , an adhesive glycoprotein  
released from the injured vessel wall, to the platelet glycoprotein Ib receptor. 
Platelet activation: 
                 Platelet are exposed to multiple agonist at the same time ( e.g.,ADP, Thromboxane  
A2,Epinephrine,Thrombin),which  triggers  a  series  of  events  within  the  platelet  ,including 
increased cytosolic calcium, cell shape change, phosphorylation of proteins, release of granules 
and  lysosomes,  arachidonic  acid  metabolism,  and  conformational  change  in  GP  IIb/IIIa 
receptor
Complex so that it becomes expressed and activate on the platelet  surface.
Platelet aggregation: 
                   50,000-80,000 GP IIb/IIIa  receptors resides on the surface of activated platelets.  
Fibrinogen is the most important ligand of GP IIb/IIIa  receptor which can bind to two GP 
IIb/IIIa  receptors simultaneously, creating a molecular platelet-to-platelet bridge.
Secondary hemostasis:
                  The principal mechanism for thrombin generation and fibrin deposition following 
plaque rupture is exposure of tissue factor , a low –molecular weight glycoprotein concentrated 
in vessel wall macrophage and vulnerable plaque. Tissue factor initiates the extrinsic pathway 
of coagulation by forming a high-affinity complex with clotting factors VII/VIIa.
                 Thrombin plays a critical role in clot formation: it converts fibrinogen to fibrin,  
activates  clotting  factors  V and  VIII  and  protein  C,  and  is  a  potent  stimulus  for  platelet 
activation  and  aggregation.  The  formation  and  polymerization  of  fibrin  is  crucial  to  clot 
stabilization and propagation,converting the unstable primary platelet plug  into an adherent 
“red” thrombus.
                                               REPERFUSION THERAPY
          Although reperfusion occurs spontaneously in some patients, persistent thrombotic 
occlusion is present in the majority of patients with AMI while the myocardium is undergoing 
necrosis23. Timely reperfusion of jeopardized myocardium represents the most effective way of 
restoring the balance between myocardial oxygen supply and demand. The extent of protection 
appears to be related directly to the rapidity with which reperfusion is implemented after the 
onset of coronary occlusion23.
          The reperfusion can be made out by 
1. Fibrinolytic therapy
2. Percutaneous Coronoray Intervention.
         In some patients, particularly those with cardiogenic shock, tissue damage occurs in a 
“stuttering” manner rather than abruptly, a condition that might more properly be termed 
subacute  infarction.  This  concept  of  the  nature  of  the  infarction  process,  as  well  as  the 
observation  that  the  incidence  of  complications  of  AMI  in  both  the  early  and  late  
postinfarction periods is a function of infarct size,underscores the need for careful history-
taking to ascertain whether the patient appears to have had repetitive cycles of spontaneous 
reperfusion and reocclusion. 
         
               “Fixing” the time of onset of the infarction process in such patients can be difficult. In 
such patients with waxing and waning ischemic discomfort, a rigid time interval from the first 
episode of pain should not be used when determining whether a patient is “outside the window” 
for benefit from acute reperfusion therapy.
PATHOPHYSIOLOGY  OF  MYOCARDIAL REPERFUSION. 
                               Prevention of cell death by the restoration of blood flow depends on the  
severity and duration of pre-existing ischemia. Substantial experimental and clinical evidence 
exists indicating that recovery of left ventricular systolic function, improvement in diastolic 
function,  and reduction in  overall  mortality  are  more favorably influenced,  the  earlier  that 
blood flow is restored8. Collateral coronary vessels also appear to play a role in the successful 
left  ventricular  function  following  reperfusion.24 They  provide  sufficient  perfusion  of 
myocardium to retard cell  death and are probably of  greater  importance in patients  having 
reperfusion later rather than 1 to 2 hours after coronary occlusion.
   Pathology of Reperfusion Injury:
           The process of reperfusion, although beneficial in terms of myocardial salvage, may 
come at a cost due to a process known as reperfusion injury . Kloner has summarized the data 
on the four types of reperfusion injury that have been observed in experimental animals.  
These consist of 
(1) lethal reperfusion injury—a term referring to reperfusion-induced death of cells that were 
still viable at the time of restoration of coronary blood flow, 
(2) vascular reperfusion injury— progressive damage to the microvasculature such that there is 
an expanding area of no reflow and loss of coronary vasodilatory reserve,25
 (3)  stunned  myocardium—salvaged  myocytes  display  a  prolonged  period  of  contractile 
dysfunction  following  restoration  of  blood  flow  owing  to  abnormalities  of  intracellular 
biochemistry leading to reduced energy production 26 , and 
(4)  reperfusion  arrhythmias—bursts  of  ventricular  tachycardia  and  on  occasion  ventricular 
fibrillation  that  occur  within  seconds  of  reperfusion.  The  available  evidence  suggests  that 
vascular reperfusion injury, stunning, and reperfusion arrhythmias can all occur in patients with 
AMI. The concept of lethal reperfusion injury of potentially salvageable myocardium remains 
controversial, both in experimental animals and in patients27.
Reperfusion Arrhythmias
        Reperfusion Arrhythmias  seen commonly following successful reperfusion are .
            1.  Transient sinus bradycardia occurs in  patients with inferior infarcts 
            2.   Premature ventricular contractions, 
            3.   Accelerated idioventricular rhythm, and
            4.   Nonsustained ventricular tachycardia 
                In experimental animals with AMI, ventricular fibrillation occurs shortly after 
reperfusion, but this arrhythmia is not as frequent in patients as in the experimental setting.  
          When present, rhythm disturbances may actually be a marker of successful restoration of  
coronary flow.
Pathophysiology of  Late Establishment of Patency of the Infarct Vessel:
              It has been suggested that improved survival and ventricular function after successful  
reperfusion are not due entirely to limitation of infarct size28. Both experimental and clinical 
evidence indicate that the benefits of a patent artery include a favorable effect on ventricular 
remodeling  (improved  healing  of  infarcted  tissue  and  prevention  of  infarct  expansion), 
enhancement of collateral flow, improvement in diastolic and systolic function, and  increased 
electrical stability, and reduced long-term mortality.
                     Late reperfusion of the artery perfusing an infarction provides a vascular 
scaffolding in the infarct zone and increases the influx of inflammatory cells that participate in 
the formation of a mature fibrous scar.The vascular scaffold and firmer myocardial scar prevent 
infarct  segment  lengthening and decrease  the  tendency  to  infarct  expansion  and  aneurysm 
formation29. Poorly contracting or noncontracting myocardium in a zone that is supplied by a 
stenosed infarct-related artery with slow antegrade perfusion may still contain viable myocytes. 
This situation is referred to as hibernating myocardium30 , and its function can be improved by 
percutaneous transluminal coronary angioplasty (PTCA) to augment flow in the infarct-related 
artery. Late reperfusion of the infarct-related artery by thrombolysis or late restoration of flow 
via PTCA enhances the electrical stability of the infarcted zone and is probably related to the 
reduced incidence of ventricular fibrillation and automatic firing of implantable cardioverter-
defibrillator devices.
     
          
                                  FIBRINOLYTIC THERAPY
Indication for fibrinolytic therapy16
Class I
1. In  the  absence  of  contraindications,fibrinolytic  therapy  should  be  administered  to 
STEMI patients with symptom onset within the prior 12 hours and ST elevation greater 
than 0.1 mV in at least 2 contiguous precordial leads or at least 2 adjacent limb leads.
2. In the  absence of contraindications,fibrinolytic therapy should be admistered to STEMI 
patients with symptom onset within the prior 12 hours  and new or presumably new 
LBBB.
Class II a
1. In the absence of contraindications, it is reasonable to administer fibrinolytic therapy to 
STEMI patients with symptom onset within the prior 12 hours and 12-lead  ECG finding 
consistent with a true posterior MI.
2. In the absence of contraindications, it is reasonable to administer fibrinolytic therapy to 
patients with symptoms of STEMI beginning within the prior 12 to 24 hours who have 
continuing  ischemic  symptoms  and  ST  elevation  greater  than  0.1  mV  in  at  least  2 
contiguous precordial leads or at least 2 adjacent limb leads.
Class III
1. Fibrinolytic  therapy should not  be  administered to  patients  whose initial  symptoms of 
STEMI began more than 25 hours earlier.
2. Fibrinolytic therapy should not be administered to patients whose 12-lead ECG shows only 
ST-segment depression except if a true posterior MI is suspected.
CONTRAINDICATION AND CAUTIONS FOR FIBRINOLYTIC THERAPY16.
Absolute contraindications
1. Any prior ICH
2. Known structural cerebral vascular lesion (eg.,AVM)
3. Known malignant intracranial neoplasm (primary or metastatic)
4. Ischemic stroke within 3 months EXCEPT acute ischemic stroke within 3 hours.
5. Suspected aortic dissection
6. Active bleeding or bleeding diathesis (excluding menses)
7. Significant closed head or facial trauma within 3 months
Relative contraindications
1. History of chronic severe, poorly controlled hypertension.
2. Severe uncontrolled hypertension on presentation (SBP greater than 180 mm Hg or DBP 
greater than 110 mm Hg)
3. History of prior ischemic stroke greater than 3 months, dementia, or known intracranial 
pathology not covered in contraindication.
4. Traumatic or prolonged (greater than 10 minutes) CPR or major surgery (less than 3 
weeks).
5. Recent (within 2 to 4 weeks) internal bleeding.
6. Noncompressible vascular punctures.
7. For streptokinase : prior exposure (more than 5 days ago) or prior allergic reaction to 
these agents.
8. Pregnancy.
9. Active peptic ulcer.
10.  Current use of anticoagulants : the higher the INR , the higher the risk of bleeding. 
Agents 
1. Streptokinase (SK):
           Dose : 1.5 million units IV over 30-60 minutes 
            Activates  circulating plasminogen to induce a systemic lytic state. Allergic reactions  
are common (most often hypotension). Least likely to cause  intracranial bleeding. Acute IV 
heparin is not necessary for reduction in mortality or reinfarction, and subcutaneous heparin 
is  of  questionable  benefit.  Heparin  is  used  in  high  risk  setting.  Avoid  reuse  due  to 
persistence of neutralizing antistreptococcal antibodies.  Acute patency rate:  50%.  Least 
expensive agent.
2. Tissue plasminogen activator (tPA)
                Dose : 100 mg IV maximum in 90 minutes: 15 mg bolus, then 0.75 mg/kg (max 50  
mg) over 30 minutes, then 0.5 mg/kg (max. 35 mg) over next 60 minutes.
             Preferentially activates clot bound plasminogen; does not induce systemic lytic state. 
No allergic  potential.  Mortality   advantage  over  SK if  accelerated  dosing  regimen and IV 
heparin are given within 4 hours of symptom onset despite a slight increase in ICH. Greatest  
benefit is for patients presenting early with large MI and low risk of ICH. Acute IV heparin is  
essential to maintain coronary patency.   Acute patency rate is 80%. It is expensive.
  
3. Recombinant plasminogen activator (rPA)  (Reteplase):
       Dose; 10U IV bolus over 2 minutes, repeated in 30 minutes x 1. Normal saline flush 
before and  after each bolus.
                 Preferentially activates clot bound plasminogen , but not as fibrin specific as tPA, 
and fibrinogen is depleted in many patients. No allergic potential. Deletion mutation of wild 
type tPA with a longer half life and reduced fibrin specificity compared to tPA. Convenient 
bolus  dosing.  Mortality  and ICH similar  to   accelerated  tPA in GUSTO-III.   Acute  IV 
heparin is essential to maintain coronary patency. Acute patency rate is 80%. It is expensive
4. TNK-tPA (Tenecteplase):
             Dose: Single, weight adjusted IV bolus over 5 seconds: < 60 kg (30 mg): 60-69 kg 
( 35 mg ); 70-79 kg (40  mg ); 80-89 kg (45mg); >90kg (50mg)
            Preferentially activates clot bound plasminogen , does not induce systemic lytic 
state.  No allergic potential. Developed by altering amino acids of wild type tPA; Longer 
half  life  and  increased   fibrin  specificity  compared  to  tPA.  Convenient   bolus  dosing. 
Mortality and ICH similar to   accelerated tPA in ASSENT-2..  Acute IV heparin is essential  
to maintain coronary patency. Acute patency rate is 80%.  It is expensive.
Adjunctive antithrombin therapy 
              Fibrinolytic therapy exposes clot bound thrombin, which is a potent stimulus for 
further platelet aggregation and fibrin generation. To offset  this  prothrombotic  potential , 
antithrombin therapy is routinely employed  particularly with tPA, rPA, and TNK-tPA. There 
is  less  need  for  systemic  anticoagulation  with  streptokinase,  as  streptokinase  results  in 
generation of fibrin degradation products and depletion of clotting factors V and VIII, which 
confer systemic anticoagulant effects.
          Heparin dosing is a balance  between the risk of occlusion and  the risk of major 
bleeding,and current recommendation  is an IV bolus dose of 60-70 U/kg (max. 5000 units) of 
unfractionated heparin followed by a continuous IV infusion of  12-15 U/kg/hr (max 1000 
U/HR), adjusted  to aPTT of 1.5-2.5 times control  for  48 hours.
                                 
Complication and management of lytic therapy:
Minor bleeding (puncture site, oral, nasal)
                Minor bleeding episode are treated by local compression. To minimize the risk of  
bleeding, compressible vascular access site should be used, vascular line should be left in 
place  for  several  hours  after  fibrinolytic  therapy  (  especially  after  streptokinase),and  the 
number of invasive procedure should be kept minimum.
Major bleeding ( GI, intracranial) 
              The incidence of GI bleeding is 5% and intracranial hemorrhage is 0.5-1.0 % after  
fibrinolytic  therapy.  Risk  factors  for  intracranial  hemorrhage,  which  is  fatal  in  50-60%, 
include  older  age  (especially  >70  years),  lower  body  weight,  history  of  cerebrovascular 
events, hypertension on presentation, and use of a fibrin specific fibrinolytic agent. Any focal 
neurological  deficit  or  significant  detoriation  in  mental  status  should  be  treated  as  an 
intracranial  hemorrhage  until  excluded  by  CT  scan.  Blood  investigation 
(  hemoglobin,hematocrit,platelet,  PT/PTT,  fibrinogen)  should  be  obtained  and  treatment 
should be started before CT result is available.
                 Immediate discontinuation of lytic , heparin, GP IIb/IIIa inhibitors, asprin, and  
clopidogrel is mandatory.protamine sulphate ( 20-50 mg IV over 1-3 minutes ) can be given to 
reverse  the effect of heparin. Packed RBCs are indicated for bleeding –induced hypotension 
or hematocrit <25%;platelet transfusions (6-10) are indicated  to reverse abciximab effect; and 
cryoprecipitate (10 units) is indicated to keep fibrinogen levels >150 mg/dl. ( Fibrinogen can 
be low or dysfunctional 6-8 hours after tPA, rPA, and TNK-tPA, and for up to 30 hours after 
streptokinase ). 
                     For persistent bleeding, fresh frozen plasma (2-3 units) and repeat cryoprecipitate 
transfusion are indicated. For continued bleeding despite these measures, additional platelet 
transfusion (even the platelet count is normal) is recommended to reverse the effect of  asprin 
and fibrin split products. Aminocapraoic acid may counteract the effect of plasmin but at a 
risk of severe thrombosis
Fever
        Fever occur in 5% of patients receiving streptokinase and is treated with asprin or  
acetaminophen.
Hypotension
        Hypotension occurs in 10-15% of patients during streptokinase infusions and is treated 
with IV fluids and by slowing or temporarily discontinuing the streptokinase  infusion until 
BP>  90  mm Hg,  then  resuming  the  normal  infusion  rate.  Hypotension  is  not  an  allegic 
reaction unless it is associated with anaphylaxis
Rash: 
     Rash occurs in 2-3% of patients receiving streptokinase and is treated by discontinuing  the 
streptokinase infusion and giving benadryl 50 mg ( IV or PO) and hydrocortisone 100 mg (IV) 
q 6h ( if severe). If   a full lytic dose was not received, 50 mg tPA or acute PCI should be  
considered.
Anaphylaxis :
     Anaphylaxis  occurs  in  0.1%  of  patients  receiving  streptokinase   and  is  treated  by 
discontinuing the streptokinase infusion, securing an airway, and giving epinephrine 1-5 cc of 
1:10000 solution IV, hydrocortisone 100-200 mg IV q 4-6 h, and IV fluids. IV dopamine is 
indicated for persistent hypotension.
Rigors
    Rigors can occur during plasminogen breakdown.
Reperfusion Arrhythmias:
Bradycardia, third degree AV block
              Occurs most often with acute reperfusion of the right coronary artery and usually  
resolves within minutes.   Symptomatic episodes are treated with atropine.  Transcutaneous 
pacing is rarely needed.
Bezold-jarish reflex:
               Presents as profound hypotension with bradycardia in response to activation of vagal  
afferent fibers following  acute reperfusion of RCA. Treated with atropine every 3-5 minutes, 
IV fluids, and possibly temporary pacing. Persistent episodes may require norepinephrine IV.
Idioventricular rhythm:
              No treatment is required for rates<120 bpm in the absence of hypotension.
Ventricular tachycardia:
            No treatment is required for runs of nonsustained VT, which are common and usually  
abate  over  time.  For  pulseless  VT  or  ventricular  fibrillation,  immediate  defibrillation  is 
required.
CHOICE OF AGENT.   
             For choosing the  thrombolytic agent between streptokinase , tPA, rPA, and TNK-tPA  
it is better to categorize patients into those that are at  ( Simoons and Arnold31)
1. High risk of death  
           Advanced age, female gender, depressed left ventricular function, anterior MI, bundle  
branch block, total magnitude of ST-segment elevation, diabetes, heart rate greater than 100 
beats/min,  systolic  pressure  less  than  100  mm  Hg,  long  delay  since  onset  of  ischemic 
discomfort. 
2. High risk of intracranial hemorrhage 
                      Age greater than 65 years. 
                          In the subgroup of patients presenting within 4 hours of symptom onset, the  
speed of reperfusion of the infarct vessel is of paramount importance and a high-intensity 
thrombolytic  regimen such as  accelerated t-PA is  the  preferred treatment,  except  in  those 
individuals in whom the risk of death is low (e.g., a young patient with a small inferior MI) 
and  the  risk  of  intracranial  hemorrhage  is  increased  (e.g.,  acute  hypertension),  in  whom 
streptokinase and accelerated t-PA are approximately equivalent choices.
                    For those patients presenting between 4 and 12 hours after the onset of chest  
discomfort, the speed of reperfusion of the infarct vessel is of lesser importance, and therefore 
streptokinase and accelerated t-PA are generally equivalent options, given the difference in 
costs
                 Patients with  low mortality risk but an increased risk of intracranial hemorrhage  
(e.g., elderly patients with inferior MI, blood pressure greater than 100 mm Hg, and heart rate 
less  than  100  beats/min),  streptokinase  is  probably  preferable  to  t-PA because  of  cost 
considerations if thrombolytic therapy is prescribed at all in such a patient4.
                In those patients considered appropriate candidates for fibrinolysis and in whom tPA 
would have been selected as the agent of choice in the past, now it is better to consider using a  
bolus thrombolytic  such as reteplase or tenecteplase. The rationale for this recommendation is 
that  these agents  has the advantage of  ease  of  administration,  a  lower chance of  medical 
errors, and less noncerebral bleeding and also offers the potential for prehospital treatment32.
LATE  THERAPY. 
                No mortality benefit was demonstrated in the LATE and EMERAS trials when  
thrombolytics were routinely administered to patients between 12 and 24 hours,33,34  but  it is 
still  reasonable  to  consider  thrombolytic  therapy  in  appropriately  selected  patients  with 
persistent symptoms and ST elevation on ECG beyond 12 hours . Persistent chest pain late 
after the onset of symptoms correlates with a higher incidence of collateral or antegrade flow 
in the infarct zone and is therefore a marker for patients with viable myocardium that might be 
salvaged. 
           Because elderly patients treated with thrombolytics more than 12 hours after the onset 
of  symptoms  are  at  increased  risk  of  cardiac  rupture,  it  is  our  practice  to  restrict  late 
thrombolytic administration to younger patients (<65 years) with ongoing ischemia, especially 
those with large anterior infarctions.             
             The elderly patient with ongoing ischemic symptoms but presenting late (>12 hours)  
is probably better managed with direct (primary) PTCA (see below) than with thrombolytic 
therapy.
Angiographic assessment
                      When assessed angiographically, flow in the culprit coronary artery is described 
by a simple qualitative scale  called the TIMI grading system: grade 0 indicates complete 
occlusion  of  the  infarct-related  artery;  grade  1  indicates  some penetration  of  the  contrast 
material beyond the point  of obstruction but without perfusion of the distal  coronary bed; 
grade 2 indicates perfusion of the entire infarct vessel into the distal bed but with flow that is  
delayed compared with that of a normal artery; and grade 3 indicates full perfusion of the 
infarct vessel with normal flow.
                Early reports frequently lumped TIMI grades 2 and 3 under the general category of 
patency, but it is now recognized that grade 3 flow is the goal of reperfusion therapy, because 
full perfusion of the infarct-related coronary artery yields far better results in terms of infarct  
size, maintenance of  left ventricular   function, and reduction of both short- and long-term 
mortality  rates.  Relatively  new  methods  of  angiographic  assessment  of  the  efficacy  of 
thrombolysis include counting the number of frames required on the cine film for dye to flow 
from the origin of the infarct-related artery to a landmark in the distal vascular bed (TIMI 
frame  count)  and  determining  the  rate  of  entry  and  exit  of  contrast  dye  from  the 
microvasculature in the myocardial infarct zone (TIMI Myocardial Perfusion Grade)35,36
Time as a determinant for success of thrombolytic therapy
          Mordern in-hospital care of the STEMI has resulted in a substantial reduction in 
mortality. Some 40 to 65 percent of death from AMI , however ,  occur within an hour of the 
onset of symptoms and prior to arrival at a hospital.  Most death are attributed to ventricular 
fibrillation . To achieve a further substantial decrease in mortality rate, it will be necessary to 
reduce the incidence of deaths outside the hospital. The earlier the thrombolytic therapy  can 
be initiated in eligible patients, the better the outcome, it is also essential to bring patients with 
chest pain into the medical care system as soon as possible because of  the need to shorten the 
time between the onset of symptoms and the initiation of thrombolytic therapy.
                  Thrombolytic therapy can reduce the relative risk of in-hospital death by up to 50%  
when administered within the first hour of the onset of symptoms of AMI, and much of this 
benefit is maintained for at least 10 years. Appropriately used thrombolytic therapy appears to 
reduce infarct  size,  limit  Left  ventricular  dysfunction, and reduce the incidence of serious 
complications such as septal rupture, cardiogenic shock, and malignant ventricular arrhythmias. 
Since myocardium can be salvaged only before it has been irreversibly injured, the timing of 
reperfusion therapy, by thrombolysis or a catheter-based approach, is of extreme importance in 
achieving maximum benefit. 
                   While the upper time limit depends on specific factors in individual patients, it is 
clear that  "every minute counts" and that  patients treated within 1 to 3 h of the onset of  
symptoms generally benefit most. Although reduction of the mortality rate is more modest, the 
therapy remains of benefit for many patients seen 3 to 6 h after the onset of infarction, and 
some benefit appears to be possible up to 12 h, especially if chest discomfort is still present and 
ST segments remain elevated in ECG leads that do not yet demonstrate new Q waves37.
             Compared with PCI for STEMI , fibrinolysis is generally the preferred reperfusion 
strategy  for patients presenting in  the first hour of symptoms, if there are logistical concerns 
about transportation of  the patients  to suitable  PCI center, or  there is  an anticipated delay of 
at least 1 hr between the time that fibrinolysis could be started versus implementation of PCI. 
Although  patients < 75 years achieve a greater relative reduction in the mortality  rate with 
fibrinolytic therapy than do older patients , the higher absolute mortality rate (15 to 25%) in the 
latter results in similar absolute reductions in the mortality rates for both groups. 
Time loss between onset of symptoms and initiation of therapy
                 Prolonged delay time in responding to patient’s symptoms is the rate limiting step in 
defining the prehospital phase of myocardial infarction. Mean time in such response is 3 hours 
38 .  Most  of  the  time  is  consumed   in  decision  making  ,  while  failing  to  recognize  or  
acknowledge the seriousness of the problem.
           Many factors influence the delay in receiving the thrombolytic therapy.
Diabetic:
           Prehospital delay has been shown to be prolonged for patients with  diabetic  40-42. 
Diabetic patients frequently present with atypical symptoms due to the presence of diabetic 
autonomic neuropathy. This atypical presentation  reduces the intention of patients to come to 
hospital  and also the diagnostic delay in hospital.43
Age:
        Due to multiple compounding factors like presence of other disease, atypical pain,  
presence of attender to take care, older age persons have prolonged prehospital delay when 
compared to younger age group
         It is possible that older people have more atypical symptoms with pathological ECG 
changes from previous myocardial damage. This combination create problems in interpreting 
ECG  and thereby increased door to needle time12.
Women :
           Some studies show significant delay in women and in others there is no gender 
difference  in  the  time  lag.  This  delay  is  attributed  to  reduced  care  and  more  atypical 
presentation.44,45
           There is tendency for physicians to show less concern for women’s ST elevation than 
men’s. Jackson et al 46 found longest delay for women  in this aspect.
Coronary Artery Disease:
             CAD patients would attribute the chest pain to the anginal pain they usually get on  
excertion  and try to self medicate them which is cause of delay.
But studies shows conflicting reports in the delay in these group of patients47.
         Other factors determining the delays are education level and blacks wait longer time than  
white.
Delay in transport to hospital
         Ambulance transportation time in most industrialized countries is of a short duration. 
Ambulance have priority  in  traffic  and are  well  identified.  In  medium sized town without 
regular traffic jams , a major gain in time in this link of the chain is not likely. In rural areas, as 
well as in  a metropole, the situation may be different, but even then the the loss of time due to  
transport is limited. In Nottingham registry, the median time time  from the patient’s call for 
the ambulance to its hospital arrival was 29 minutes(Rowley,1992). 
            There is a striking difference in delay in delay of hospital admission between patients  
who choose to call a general practitioner compared to those who choose to call an emergency 
ambulance. If a general practitioner referred  the patient to the hospital, median delay was 247  
minutes, compared with 100 minutes when the patient called an ambulance directly .
Strategy to reduce the time from onset of symptoms to treatment 
                 Health care professionals should heighten the level of awareness of patients at risk 
for AMI (e.g., those with hypertension, diabetes, history of angina pectoris, old age ). They 
should  review  and  reinforce  with  patients  and  their  families  the  need  for  seeking  urgent 
medical attention for a pattern of symptoms including chest discomfort, extreme fatigue, and 
dyspnea, especially if accompanied by diaphoresis, lightheadedness, palpitations, or a sense of 
impending doom.48 
              This education   should be continuous. Information of the public to reduce time from 
symptom onset  to  medical  service  call  have  shown success  only  during  the  time  the  continuous 
publicity was maintained. Soon after the end of such activities the prehospital delay again reached the 
initial duration49. 
                 Patients should also be instructed in the proper use of sublingual nitroglycerin that  
should be taken as one tablet at the onset of ischemic-type discomfort and repeated at 5-minute 
intervals for a total of three doses. If the symptoms have not dissipated within 15 minutes, the 
patient should be rapidly transported to a medical facility that has the capability of recording 
and interpreting an electrocardiogram,  providing advanced cardiac life support  and cardiac 
monitoring,  and  initiating  reperfusion  therapy  with  either  thrombolysis  or  angioplasty  if 
indicated. Primary care physicians need to take a larger role in helping implement strategies to 
facilitate early treatment.48
                   Well-equipped ambulances and helicopters staffed by personnel trained in the acute 
care of the infarction victim (mobile CCUs) allow definitive therapy to commence while the 
patient is being transported to the hospital. 
                  Trained paramedics can reliably diagnose myocardial infarction by ECG. The use of a 
direct admission procedure, by a radio link to the CCU, substantially reduces the time interval for 
thrombolytic treatment after acute myocardial infarction50
   PREHOSPITAL THROMBOLYSIS. 
                 The potential benefits of prehospital thrombolysis have been evaluated in several 
randomized trials . Although none of the individual trials showed a significant reduction in 
mortality  with  prehospital  initiated  thrombolytic  therapy,  there  was  a  generally  consistent 
observation of benefit  from earlier treatment,  and a meta-analysis of all  the available trials 
demonstrated a 17 per cent reduction in mortality 51. 
               The CAPTIM trial reported a trend toward a Lower rate of mortality among STEMI  
patients  receiving prehospital  fibrinolysis  as  compared with primary  PCI,  especially  if  the 
patient  was  treated  with  in  2  hours  of  the  onset  of  symptoms.  Additional  benefit  from 
prehospital  benefit  is found in a report of French registry of STEMI patient treated less than 
12 hours from the onset of symptoms; the 1 month mortality rate was 14.7 percent in patients 
who do not receive reperfusion, 9 percent in those treated with in-hospital fibrinolysis,  7.9 
percent  in  those  treated  with  primary  PCI  and  3.2  percent  in  those  receiving  prehospital 
fibrinolysis52.
             Several factors must be weighed when communities consider whether their ambulances 
and emergency transport vehicles should have capabilities of initiating thrombolytic therapy. 
The greatest reduction in mortality is observed when reperfusion can be initiated within 60 to 
90 minutes of the onset of symptoms.
                 It has been suggested that the streamlining of emergency department triage practices 
so that treatment can be started within 30 minutes, when coupled with the 15 to 30 minute 
transport  time  that  is  common  in  most  urban  centers,  may  be  more  cost  effective  than 
equipping all  ambulances  to  administer  prehospital  thrombolytic  therapy.  The  latter  would 
require extensive training of personnel, installation of computer-assisted electrocardiographs or 
systems for radio transmission of the ECG signal to a central station, and stocking of medicine 
kits with the necessary drug supplies.
                       However, in selected communities where transport delays may be 90 minutes or  
longer  and  experienced  personnel  or  physicians  are  available  on  ambulances,  prehospital 
thrombolytic therapy is probably beneficial 53.
                A thrombolysis nurse produced a dramatic improvement in median door-to-needle  
and  pain-to-needle  times  in  patients  presenting  with  definite  MI.  This  would  lead  to  an 
additional 41 lives saved at 30 months per 1,000 patients treated54.   Emergency department 
staff may be alerted to the sudden development of ST segment elevation by periodic visual 
inspection of the bedside ECG monitor, by continuous ST-segment recording, or by auditory 
alarms when the ST-segment deviation exceeds programmed limits.
        In a study done at department of cardiology, oxford , UK, an aggressive policy is used to  
reduce the door to needle time. This lead to increased propotion of eligible patients to receive 
thrombolysis early.  However, greater pressure on medical staff to make rapid management 
decisions increased the proportion of patients being thrombolysed inappropriately55    The time 
taken to administer thrombolysis to patients admitted with acute myocardial infarctions can be 
reduced by focusing on the delay by Registration of hospital time56  
               Physicians evaluating patients in the emergency department must confront the  
difficult task of rapidly identifying patients who require urgent reperfusion therapy, triaging 
lower risk patients to the appropriate facility within the hospital, and not discharging patients 
home inappropriately while avoiding unnecessary admissions.
 
  
                                        MATERIALS AND METHODS
Study sample.
 For  the  present  investigation  the  sample  includes  107   patients  with  STEMI 
consecutively  admitted  to  intensive  coronary  care  units  in  Stanley  medical  college  during 
period of June 2004 to October 2004 . 
                Patients included in the study   are the one  who had   a   typical electrocardiogram 
changes including  ST elevation greater than 0.1 mV in at least 2 contiguous precordial leads or 
at least 2 adjacent limb leads or new or presumably new LBBB.  with a  typical changes in the 
levels of serum enzyme
 with or without  chest pain lasting > 30 minutes.  
                Patients with symptoms of acute coronary syndrome with NSTEMI , unstable angina 
were excluded .
Study variables.
On  admission  patient’s  clinical  profile,  electrocardiographic  data,  information  on 
administration of thrombolytic agents and complication if any were noted and investigation for 
cardiac enzymes and plasma sugar were taken and noted
 During  the  hospital  stay  the  patients  were  interviewed and completed  a  standard 
record form covering details of their past medical history. The time of onset of AMI symptoms 
was recorded as accurately as possible. For some patients (i.e., patients with cardiogenic shock, 
signs of dementia,etc.) this information was obtained from family members. The time of entry 
to hospital was recorded. The time of admission to the coronary care unit was recorded and so 
is the time of start of thrombolytic therapy .The pre-hospital time interval  was defined as the 
time interval from the beginning of the most recent onset of chest pain or the latest episode of  
intensified or prolonged pain to entry to hospital. 
Study variables included: age, gender, alcohol consumption, cigarette smoking,  hypertension, 
diabetes  mellitus,  history  of  coronary  artery  disease  (documented  history  of  angina  and/or 
myocardial infarction), location of MI,.
Statistical analysis.
 
The  time delays  were  expressed  in  minutes. Treatment  delay  data  had a  skewed 
distribution(Fig1,2); therefore all data are processed with medians and range. The significance 
of differences in median times was determined using a Mann–Whitney U-test. Two-tailed  P-
values  <0·05  were  considered  statistically significant.  For  better  understanding  data  are 
presented as medians (range) and mean (SD).
                                            RESULTS
     One hundred and seven  consecutive   STEMI patients were studied with mean age 
of 53.80. Out of this 89 received thrombolytic therapy. The patients characteristic are presented 
in Table 1.
                                     Table 1
        The Median time from onset of symptoms to arrival at emergency department was 155 
minutes and Median time from hospital arrival to thrombolysis was 40 minutes . The various 
delay  were  shown  in 
median as there is skewed distribution (Table 2)
                                                    Table 2
                           
Time Median (range)
Onset  of  chest  pain  to  patient’s  initiation  to  go  to 
hospital 
45 (5-1120)
Transportation time 45  (15-430)
Delay due to private consultation  (74/107) 35  (10-1185)
Prehospital delay 155  (40-1260)
Door to needle time in thrombolysed  (89/107) 40  (15-685)
Total delay 200  (70-1340)
 
              
ANALYSIS OF PATIENT’S CHARACTERISTIC ON DELAY
1.Age 
   Prehospital time                   Table 3
. Door to needle time : 
                    89 patients are thrombolysed and analysed for door to needle time
                                                    Table 4
 2.  Sex
    Prehospital  time                     Table 5      
       Door to needle time:             Table 6
 3. Diabetic  
    Prehospital time                  Table 7
Test Statistics(a)
                            Mann-Whitney U          P-value = 0.033 
          
  Door to needle time                 Table 8       
  
4. Hypertension 
Prehospital  time                        Table 9
Door to needle time                      Table 10
                                                      P value <0.001
5.Previous history of CAHD
Pre hospital time                           Table 11
Door to needle time                     Table 12
6. Smokers 
Prehospital  time                     Table 13
        Test Statistics
                            Mann-Whitney U                 p value = 0.028
Door to needle time                   Table 14
7. Alcoholic 
Prehospital time                   Table 15
Door to needle time                   Table 16
8.  Location of MI
Prehospital time                 Table 17                          
Door to needle time                 Table 18
 
Patients seeking treatment from private practitioner delayed longer than who came directly to 
tertiary hospital.
                                                             Table 19
  
             
                             P value <0.05
                
                                                              DISCUSSION
               This study is to describe the various  time intervals leading to delay in thrombolytic  
therapy  and  to  describe  the  influence  of  patient’s  clinical  characteristics  to  delay  in 
thrombolytic therapy in the sample of patients admitted to coronary care unit for STEMI  from 
June 2004 to October 2004.
            Of  107  STEMI  patients studied 91 were male and 16 were females  with mean age of  
53.80 with a SD of 11.50. 15.9% (17) of patients were above 65 years age group. 
            89 patients ( 83.2%) were thrombolysed  out of  total 107 patients. 18 of them did not  
receive  thrombolytic  therapy.  Prehospital  delay  was  the   cause  for  11  of  18  patients  not 
receiving  thrombolytic  therapy,  remaining  are  due  to  contraindications  like  accelerated 
hypertension in 4, previous use of streptokinase in 1 , stroke in 1, and bleeding complication in 
1 leading to termination of thrombolysis 
                In this study group  19.6% ( 21/107)  of patients were diabetic , 23.4% (25/107) were 
hypertensive and 9.3% (10/107 ) of them had previous  history of angina and/or myocardial 
infarction.
             61 of the patients had anterior wall MI and 46 of them had  inferior wall MI.
               In this study the median  prehospital time was155 minutes and the door to needle time 
was 40 minutes.. Prehospital time was calculated for all the 107 patients and door to needle 
time was calculated for the 89 patients who were thrombolysed.
             A   review of data from various  studies published through out the world vary from 83 
min to 300 min (median time) for prehospital delay and for Door to needle time it is between 
30  to  95  minutes(median  time).  These  differing  delay  are  likely  attributable  to  varying 
demographic and clinical characteristics of samples under study, definition of symptom onset 
used and period during which study is conducted. In an Indian study done in PGI, Chandigar 
median prehospital delay was 5.2 hours and Door to needle time was 60 minutes57.
Extract of various studies are as follows 
Median Delay (min)
                                     Pre-hospital      In-hospital        Total
Birkhead et al.58                    103             31*                   na
Gonzalez et al.59                     na              50                   155
Herlitz et al.60                         98              50                   200
Porter et al.61                         150             40                    na
Newby et al.14                         92             64                   168
Rustige et al.62                         na             30                   160
Anne- Maree Kelly et al 12      83             37                     na
Di Chiara Aet al 13                 129             45                     na 
Abba AA et al 63                    300             95                     na
Constantine et al 64                 130            85                     na
*Thrombolysis given in the Accident and Emergency department.
         
              On analyzing the patient’s characteristics it was found that diabetic presented to  
hospital 260 minutes(median time ) after the onset of symptoms of Myocardial infarction when 
compared to nondiabetic who came with median time of 150 minutes . This shows that there 
was a significant pre hospital delay in diabetics (p<0.05) and suggest  that  diabetic sensory 
neuropathy causing attenuation of symptoms was responsible. This finding is almost universal 
and found in all studies 40-43
               When Age is considered, older persons have a mean  door to needle time of 99.33  
minutes when compared to the younger  who have a mean delay of  50 minutes .This  is due to  
atypical presentation  and difficulties in eliciting proper history. 65
               The median door to needle time in hypertensives was 70 minutes when compared to 
normotensives whose door to needle time was 40 minutes (p<0.001) A higher prevalence of 
previous  myocardial  damage  and  myocardial  hypertrophy  might  have  induced   ECG 
abnormalities , creating problems in the early interpretation of the ECG along with the fear of 
increased risk for Intracerebral hemorrhage  caused unnecessarily  long delay times in hospital 
41. 
              Non Smokers have significant prehospital delay when compared to smoker (p< 0.05). 
This  may probably due to increased awareness among the smoker .  Delay was not significant 
for female sex, previous history of CAD,  which was same as of North Indian study 57 but other 
western study shows significant delay in them 41,42.
                The location of MI does not significantly alter the  prehospital delay  or Door to 
needle time similar to western study. (Giuseppe Berton et al) 65.
                 Of  the prehospital time,  time interval between the onset of chest pain to patient’s 
initiation to go to hospital was 45 minutes and this timing is not studied in detail in previous 
studies  Hirvoven,T.P.J et al 66shows  the median time interval between the onset of chest pain 
to patient’s initiation to go to hospital was 60 minutes . Transportation to hospital consumes a 
median time of 45 minutes 
           69.15% (74/107) of the patients consulted the local practitioner before coming to tertiary 
hospital. Prehospital delay was significantly higher in patients (167.5 Vs 90 min p<0.05) who 
had visited a local practitioner than those who came straightaway to the emergency unit of the 
hospital. This finding is similar with the Indian study 57  
Limitations of the study:  patient who died of AMI outside the hospital and those with silent MI 
who are not presented to hospital  were not studied.
  
      
                                                            CONCLUSION
           The present study shows that in case of STEMI, the time interval between onset of 
symptoms and patient’s arrival is still far from optimal and Door to needle time is comparable 
with other countries.
            Diabetic patients present to hospital late and Door to needle time was   higher for  
hypertensives.
          The other main factors contributing to prehospital delay are prior consultation with the 
local practitioner and unavailability of rapid transport facilities.
            The best way to minimize delay  is probably by a public education campaign with a  
correctly designed message, ( particularly   Diabetics and Elderly persons should be explained 
about the  symptoms of AMI ) and to increase public awareness to use ambulance transport to 
hospital.  The  emergency  department  should  constantly  develop  protocol  and  guidelines  to 
assure rapid identification of AMI patients. 
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                                                                   PROFORMA
NAME:                                                                IP NO:
AGE:                                                                    ADDRESS:
SEX: 
OCCUPATION




3. coronary heart disease
4. other illness 
PERSONAL HISTORY:
1. Smoking                 No of cigarettes /day:      Duration in years:
2. alcohol
Time of onset of chest pain or anginal eqvualent:
Time of initiation to go to hospital:
Time interval between starting of chest pain 
                      to patient’s initiation to go to hospital:
Reason’s if any for patient’s time delay :
Time taken to arrange for transport:
Duration of transport:
Total delay for transport:
Mode of transport:
Distance of the place from Stanley:
Consulting time with local practitioner:
           Immediate referral to tertiary hospital:
           ECG taken and referred: 
Time of entry into emergency department:
Time at which the ECG taken( printed in ECG):
Time of entry into cardiac care unit:
Time of starting of thrombolytic therapy:
Reason for delay or reason for  not thrombolysing:   
CLINICAL EXAMINATION:






   Plasma sugar (Fasting):
    S- CPK MB:
    Electrocardiogram:                                         Location of MI:                          
S .No Age Sex Diabetes Hyper- 
tension
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CAD- Coronary Artery Disease
Patient time - Time interval between starting of chest pain to patient’s 
                        initiation to go to hospital
Local consult – time delay due to consultation with local practitioner
Prehosp - Time interval between starting of chest pain to entry into hospital.
DTN – Door To Needle time.





















































































                             
                                          Diabetes and time interval
Time in minutes












                                            Hypertension and time interval






















           Prehospital time and delay due to prior local consultation
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